Margot Petit
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Margot Petit has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Federica Vecchio
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France
2 shared publications - Orlando Burgos Morales
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France
2 shared publications - Roberto Mallone
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France
2 shared publications - Sylvaine You
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France
2 shared publications - Alexia Carré
Université Paris Cité, Institut Cochin, CNRS, INSERM, Paris, France
1 shared publication - Amelia K. Linnemann
Department of Pediatrics Indiana University School of Medicine Indianapolis Indiana USA
1 shared publication
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eaef5067
Coxsackievirus B escapes antiviral CD8 + T cells but triggers robust CD4 + memory responses
Coxsackieviruses B (CVBs) are plausible triggers of the pancreatic islet autoimmunity leading to type 1 diabetes. Islet autoantibody seroconversion correlates with persistent CVB infections in the gut and pancreas, suggesting defective antiviral control and the need to define immune mechanisms at the intestinal entry site. We investigated how CVB3 modulates antigen presentation, the viral immunopeptidome of enterocytes and antigen-presenting cells, and downstream T cell immunity. CVB3-infected enterocytes evaded immune recognition by down-regulating human leukocyte antigen (HLA) class I and viral peptide presentation, impairing CD8 + T cell responses in vitro. In CVB-seropositive individuals, circulating CVB-reactive CD8 + T cells were stalled in naïve-like and exhausted effector/memory states. In contrast, CVB3 induced HLA class II up-regulation, promoting robust CD4 + T cell activation. Circulating CVB3-reactive CD4 + T cells fully differentiated into polyfunctional T helper memory. These findings indicate that CVB3 antiviral control is predominantly CD4 + T cell mediated and provide a rationale for mucosal vaccination strategies and immune monitoring tools to follow infection or vaccination.
- 19 June 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (25) , eaef5067
Open AccessCoxsackievirus B escapes antiviral CD8 + T cells but triggers robust CD4 + memory responses
Coxsackieviruses B (CVBs) are plausible triggers of the pancreatic islet autoimmunity leading to type 1 diabetes. Islet autoantibody seroconversion correlates with persistent CVB infections in the gut and pancreas, suggesting defective antiviral control and the need to define immune mechanisms at the intestinal entry site. We investigated how CVB3 modulates antigen presentation, the viral immunopeptidome of enterocytes and antigen-presenting cells, and downstream T cell immunity. CVB3-infected enterocytes evaded immune recognition by down-regulating human leukocyte antigen (HLA) class I and viral peptide presentation, impairing CD8 + T cell responses in vitro. In CVB-seropositive individuals, circulating CVB-reactive CD8 + T cells were stalled in naïve-like and exhausted effector/memory states. In contrast, CVB3 induced HLA class II up-regulation, promoting robust CD4 + T cell activation. Circulating CVB3-reactive CD4 + T cells fully differentiated into polyfunctional T helper memory. These findings indicate that CVB3 antiviral control is predominantly CD4 + T cell mediated and provide a rationale for mucosal vaccination strategies and immune monitoring tools to follow infection or vaccination.
- Open Access
PRV-101 Coxsackievirus B vaccine elicits protective T follicular helper immunity while avoiding cytotoxic T-cell responses in humans: implications for type 1 diabetes prevention
PRV-101 is a multivalent formalin-inactivated Coxsackievirus B (CVB) vaccine developed to prevent CVB infections, which are associated with increased risk of islet autoimmunity. While PRV-101 induces robust neutralizing antibody responses, its T-cell immunogenicity is unknown. We analyzed peripheral blood mononuclear cells from 25 healthy adults receiving three high or low PRV-101 doses or placebo in a Phase I randomized, placebo-controlled trial. CVB-reactive CD8⁺ T-cell responses were assessed using HLA Class I multimers, and CD4⁺ and T follicular helper (Tfh) responses were measured by activation-induced marker assays following stimulation with a CVB peptide library. PRV-101 elicited minimal CVB-reactive CD8⁺ T-cell responses but robust CD4⁺ and Tfh responses, peaking at week 12 and persisting through week 32. Responses were observed in both seronegative and seropositive individuals, consistent with effective immune priming and boosting. Tfh frequencies correlated with neutralizing antibody titers. Female participants exhibited higher peak Tfh responses than males. We conclude that PRV-101 elicits a CVB-protective immune profile, dominated by Tfh responses supporting durable humoral immunity and devoid of potentially diabetogenic cytotoxic T-cell responses. This profile invites further investigations in vaccine trials for type 1 diabetes prevention.
Open AccessPRV-101 Coxsackievirus B vaccine elicits protective T follicular helper immunity while avoiding cytotoxic T-cell responses in humans: implications for type 1 diabetes prevention
PRV-101 is a multivalent formalin-inactivated Coxsackievirus B (CVB) vaccine developed to prevent CVB infections, which are associated with increased risk of islet autoimmunity. While PRV-101 induces robust neutralizing antibody responses, its T-cell immunogenicity is unknown. We analyzed peripheral blood mononuclear cells from 25 healthy adults receiving three high or low PRV-101 doses or placebo in a Phase I randomized, placebo-controlled trial. CVB-reactive CD8⁺ T-cell responses were assessed using HLA Class I multimers, and CD4⁺ and T follicular helper (Tfh) responses were measured by activation-induced marker assays following stimulation with a CVB peptide library. PRV-101 elicited minimal CVB-reactive CD8⁺ T-cell responses but robust CD4⁺ and Tfh responses, peaking at week 12 and persisting through week 32. Responses were observed in both seronegative and seropositive individuals, consistent with effective immune priming and boosting. Tfh frequencies correlated with neutralizing antibody titers. Female participants exhibited higher peak Tfh responses than males. We conclude that PRV-101 elicits a CVB-protective immune profile, dominated by Tfh responses supporting durable humoral immunity and devoid of potentially diabetogenic cytotoxic T-cell responses. This profile invites further investigations in vaccine trials for type 1 diabetes prevention.